Department of Clinical and Biological Sciences, Faculty of Medicine S. Luigi Gonzaga, 10043, Orbassano, Torino, Italy.
Mini Rev Med Chem. 2011 Sep;11(10):888-900. doi: 10.2174/138955711796575498.
New antimicrobials able to counteract bacterial resistance are needed to maintain the control of infectious diseases. The last 40 years have seen the systematic tailoring and refinement of previously identified antibiotics, to produce a multitude of semi-synthetic derivatives that share their mechanism of action with the original molecules. The major limit of this approach is the emergence of multi- and cross-resistant bacterial strains, favoured by the selective pressure inherent to the targeting of specific enzymes. The most promising new strategies aim to the development of molecules that, targeting essential bacterial structures instead of specific enzymatic activities, achieve infection control without enforcing a selective pressure on bacteria. This review, based on the consultation of the up-to-date literature, deals with antimicrobial peptides and some antivirulence factors.
需要新的能够对抗细菌耐药性的抗菌药物来维持传染病的控制。在过去的 40 年中,人们系统地对以前确定的抗生素进行了修饰和改进,产生了许多具有与原始分子相同作用机制的半合成衍生物。这种方法的主要局限性是多药和交叉耐药细菌菌株的出现,这是由于靶向特定酶的选择性压力所致。最有前途的新策略旨在开发靶向细菌必需结构而不是特定酶活性的分子,从而在不对细菌施加选择性压力的情况下实现感染控制。这篇综述基于对最新文献的查阅,涉及抗菌肽和一些抗病毒因子。